Cardioxyl Pharmaceuticals

David Epstein , who departed from the leadership of Novartis Pharmaceuticals in mid-2016, has been appointed executive partner at Boston-based venture capital firm Flagship Pioneering. His first invo

Dr. Mike Burgess, senior vice president of discovery medicine and clinical pharmacology at Bristol-Myers Squibb Co. and the head of the company's cardiovascular, fibrosis, immunoscience and geneti

At a time of great success for its cancer immunotherapy Opdivo , Bristol-Myers Squibb Co. is keenly aware of the need to invest in tomorrow's up-and-coming oncologics and to keep the momentum goi

Financings Fourth-quarter 2015 biopharma financing reached $13.1 billion, 35% more than Q3’s $9.7 billion, but the second-lowest quarter of the year (behind Q3) in dollars raised. ( See Exhibit 1. ) H